3rd Quarter - Report — NCHC ACTION FUND for NCHC ACTION FUND (2017)

Firm

NCHC ACTION FUND

Client

NCHC ACTION FUND

Income

—

Expenses

$10,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017

Lobbyist	Covered position, as disclosed
JOHN ROTHER	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: S. 934 (115th), S. 974 (115th), H.R. 2430 (115th), S. 1131 (115th), H.R. 2051 (115th), H.R. 2439 (115th)

Health Issues HCR

Lobbyist	Covered position, as disclosed
JOHN ROTHER	—

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 934 (115th), H.R. 2430 (115th), S. 974 (115th), H.R. 2051 (115th), S. 1131 (115th), H.R. 2439 (115th)

Medicare/Medicaid MMM

Prescription Drug Pricing

Lobbyist	Covered position, as disclosed
JOHN ROTHER	—

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.